ISTA Financial Facts
Product sales, net: 34.01MTotal costs and expenses: 37.89M
See Full Income Statement
Total liabilities: 189.57M
Deferred financing costs, net: 759K
See Full Balance Sheet
ISTA Pharmaceuticals Inc. (ISTA) Earnings
|
Expand Research on ISTA
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -83.1% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -4.9% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2/23/12  |
 |
Q411 | $0.25 | $0.21 | +$0.04 | $45.1M | $46.55M | N/A |  | | Details |
| 11/1/11 |
|
Q311 | $0.09 | $0.11 | -$0.02 | $41.4M | $43.34M | = | | | Details |
| 7/28/11 |
|
Q211 | -$0.11 | $0.05 | -$0.16 | N/A | $41.94M | = | | | Details |
| 5/4/11 |
|
Q111 | -$0.17 | -$0.15 | -$0.02 | $36.7M | $39.25M | = | | | Details |
| 2/23/11 |
|
Q410 | $0.14 | $0.09 | +$0.05 | $51.1M | $46.78M | = | | | Details |
| 11/2/10 |
|
Q310 | $0.08 | $0.04 | +$0.04 | N/A | N/A | N/A | | | Details |
